High-Value Federal Grants ($5M+) — May 20, 2026

Northrop Grumman secured a $569.5M firm-fixed-price delivery order from NASA for the JPSS-2 polar satellite, with performance through April 2028. This full-and-open competition win reinforces its competitive moat in large space systems and adds a stable, long-duration revenue stream to its space segment.

RTX Corp (Raytheon) won a $200M cost-plus-award-fee contract from NASA for Landis flight instruments, with potential value of $506.7M through 2037. The cost-plus structure reduces profit risk, and the full-and-open competition signals RTX's competitive strength in specialized aerospace R&D.

Venatorx received a $72.1M cost-plus-fixed-fee BARDA contract (potential $318.6M with options) for an antibiotic targeting antimicrobial resistance and biothreat pathogens. This aligns with growing HHS/ASPR biodefense budgets and could catalyze further option exercises through 2032.

The $569.5M firm-fixed-price structure for the JPSS-2 spacecraft shifts cost overrun risk to Northrop Grumman. Any schedule delays or technical issues on this critical polar satellite mission could compress margins, despite the contract's strategic importance.

Northrop Grumman's $569.5M firm-fixed-price JPSS-2 spacecraft contract exposes the company to cost overruns on a complex space vehicle program. Any delivery delays or technical issues could compress margins.

All 11 contracts were awarded in periods subject to Continuing Resolution risk (Oct-Dec awards are vulnerable). The $98.8M Leidos DHS/CBP contract and $151.7M Magellan Federal DOI contract could face funding delays if CRs persist.

Caltech received two NASA awards totaling $515.4M ($445M + $70.4M), representing 27.5% of total digest value. This concentration in a nonprofit entity limits direct public equity exposure and signals NASA's reliance on JPL management.

The $151.7M Magellan Federal DOI contract has 24 subawards totaling $45.9M (30% pass-through), indicating the company acts as a prime integrator rather than direct service provider. This structure is vulnerable to re-compete losses if subcontractors bid directly.

Northrop Grumman's $569.5M JPSS-2 win positions it for follow-on NASA/NOAA polar satellite procurements. The 13-year performance period provides a platform for additional space systems contracts as the U.S. invests in next-generation weather satellites.

RTX Corp's $200M Landis contract has options that could expand total value to $506.7M through 2037. NASA's sustained investment in Earth science instrumentation suggests high likelihood of option exercise, providing RTX with a multi-decade revenue stream.

Venatorx Pharmaceuticals' $72.1M BARDA contract (potential $318.6M) targets antimicrobial resistance, a bipartisan priority. With HHS/ASPR biodefense budgets increasing, option exercises through 2032 could provide significant upside for this small-cap biotech.

Four NASA contracts totaling $1.28 billion (68.5% of digest value) underscore the agency's robust investment in space R&D and satellite programs. Northrop Grumman's $569.5M JPSS-2 and RTX's $200M Landis contract highlight demand for advanced space systems and Earth science instrumentation.

Three contracts totaling $290.8M (Deloitte $69.7M, SOFTRAMS $68.4M, Magellan Federal $151.7M) reflect sustained civilian agency demand for IT services and program support. These contracts are stable but offer limited margin expansion due to T&M and fixed-price structures.

Two HHS/BARDA contracts totaling $134.8M (Venatorx $72.1M, SELUX $62.6M) highlight sustained government investment in medical countermeasures. The cost-plus structures reduce contractor risk, and the bipartisan support for pandemic preparedness suggests stable funding.

{"entity"=>"Northrop Grumman", "reason"=>"JPSS-2 spacecraft delivery milestones and cost/schedule performance on $569.5M fixed-price contract", "trigger"=>"NASA quarterly program reviews and JPSS-2 delivery date announcements"}

{"entity"=>"RTX Corp", "reason"=>"Option exercise on $200M Landis flight instrument contract; potential expansion to $506.7M", "trigger"=>"NASA budget allocations for Earth science programs and option exercise decisions"}

{"entity"=>"Venatorx Pharmaceuticals", "reason"=>"Option exercises on $72.1M BARDA contract (potential $318.6M) and clinical/regulatory milestones", "trigger"=>"BARDA budget appropriations for AMR programs and FDA updates on antibiotic candidate"}

{"entity"=>"Leidos", "reason"=>"DHS/CBP $98.8M non-intrusive inspection systems contract; potential extension to 2033", "trigger"=>"DHS budget appropriations for border security technology and option exercise announcements"}

{"entity"=>"Magellan Federal (Centene)", "reason"=>"DOI $151.7M personal financial counselors contract; 30% pass-through subaward structure", "trigger"=>"DOI option year exercise rate and re-compete announcements"}